trimethyl-(3-hydroxy-butyl)-ammonium hydroxide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: trimethyl-(3-hydroxy-butyl)-ammonium hydroxide
• 英文别名: Trimethyl-(3-hydroxy-butyl)-ammoniumhydroxyd；Trimethyl-(γ-oxy-butyl)-ammoniumhydroxyd；3-Hydroxy-butylammonium；3-Hydroxybutyl(trimethyl)azanium
• 化学式: C₇H₁₈NO
• 分子量: 132.226
• InChiKey: JWLVVWBHILZADA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  trimethyl-(3-hydroxy-butyl)-ammonium hydroxide 生成 3-丁烯-2-醇
  参考文献：
  名称：

  DE233519

  摘要：

  公开号：

文献信息

• Thermoreactive water borne compositions based on stable polyurethane dispersions or solutions
  申请人：ENICHEM S.p.A.

  公开号：EP0741153A1

  公开（公告）日：1996-11-06

  Thermoreactive water-borne compositions based on stable polyurethane dispersions or solutions comprising: a) at least one prepolymer containing hydrophilic groups, having as chain termination a totally or partially blocked isocyanic function, with a NCO groups content of less than 12% by weight and in which the NCO free groups vary from 0 to 6% by weight with respect to the weight of the prepolymer; and b) at least one trimerization catalyst.

  基于稳定聚氨酯分散体或溶液的热活性水性组合物，包括 a) 至少一种含有亲水基团的预聚物，其链端具有完全或部分阻断的异氰酸酯官 能团，其 NCO 基团含量低于 12%（按重量计），其中 NCO 游离基团占预聚物重量的 0% 至 6%（按重量计）；以及 b) 至少一种三聚催化剂。
• IONTOPHORESIS DELIVERY OF CATIONIC PRODRUGS FOR TOPICAL TREATMENT OF MUSCULOSKELETAL OR SKIN DISEASES
  申请人：Yan Guang

  公开号：US20150297718A1

  公开（公告）日：2015-10-22

  The present invention provides a method for topical delivery of pharmacologically active chemicals into local tissues (skin, subcutaneous, muscle and joint tissues) via the administration of their specially designed cationic prodrugs with anode iontophoresis. The pharmacologically active chemicals are either negatively charged or neutral under the physiologic pH, which are not suitable to be delivered with the anode iontophoresis. The cationic prodrugs of such pharmacologically active chemicals are suitable for anode iontophoresis for improving delivery efficiency of these drugs into the local tissues. The cationic prodrugs can also be used in co-delivery with other cationic drugs such as vasoconstrictors or local anesthetic agents by iontophoresis for treatment of disorders in the local tissues. The anode iontophoresis delivery of the specially designed cationic prodrugs can provide higher drug concentrations in the local tissues, which can be used for better topical treatment of musculoskeletal diseases or skin diseases.